{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T08:35:48Z","timestamp":1778056548266,"version":"3.51.4"},"reference-count":46,"publisher":"Becaris Publishing Limited","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) for medical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF. This study evaluates the cost\u2013effectiveness and budget impact of initiating apixaban and switching to rivaroxaban versus initiating and continuing apixaban for patients with NVAF, from a German payer perspective.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            Built on an existing model, a cohort-level lifetime Markov model was developed, including dynamic pricing assumptions to account for anticipated generic entry of DOACs. The modeled population (n\u00a0=\u00a01000) included German patients with NVAF, eligible for oral anticoagulation, who initiated on apixaban. The primary model outcome was the incremental cost\u2013effectiveness ratio, assessed using cost per quality-adjusted life year (QALY) gained and a willingness-to-pay threshold of \u20ac48,750\/QALY. A secondary model outcome was a 5-year budget impact analysis.\n            <jats:bold>Results:<\/jats:bold>\n            Switching patients from apixaban to rivaroxaban led to 285 additional events per 1000 patient years, resulting in 0.079 fewer QALYs and higher total costs per patient (\u20ac21,357 vs \u20ac16,390 for apixaban continuers). In the base case analysis (with generic pricing assumptions), switching from apixaban to rivaroxaban was dominated (i.e., less effective and more costly) by continuing apixaban. In the budget impact analysis (with generic pricing assumptions), switching from apixaban to rivaroxaban led to additional cumulative costs of \u20ac490 per patient over 5\u00a0years.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Despite the introduction of generic discounting, switching patients with NVAF from apixaban to rivaroxaban led to higher total costs and fewer QALYs under base case assumptions, meaning apixaban switchers were dominated by apixaban continuers from a German payer perspective. Switching patients from apixaban to rivaroxaban also led to greater budget impact over 5\u00a0years.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0008","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T08:47:27Z","timestamp":1747817247000},"source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2013effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting"],"prefix":"10.57264","author":[{"given":"Rupesh","family":"Subash","sequence":"first","affiliation":[{"name":"Pfizer Ltd, Walton Oaks, Surrey, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Strakosch","sequence":"additional","affiliation":[{"name":"FIECON, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, NJ, US"},{"name":"University of Southern California, LA, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Hagan","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Company, NJ, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"Dworatzek","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1486-8795","authenticated-orcid":false,"given":"Agnes","family":"Kisser","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasileios","family":"Vasilopoulos","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Salter","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-0902","authenticated-orcid":false,"given":"Carissa","family":"Dickerson","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1446-4607","authenticated-orcid":false,"given":"Ewa","family":"Stawowczyk","sequence":"additional","affiliation":[{"name":"Health Economics &amp; Outcomes Research Ltd, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"100786","DOI":"10.1016\/j.lanepe.2023.100786","article-title":"Atrial fibrillation: epidemiology, screening and digital health","volume":"37","author":"Linz D","year":"2024","unstructured":"Linz D, Gawalko M, Betz K Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg. Health Eur. 37, 100786 (2024).","journal-title":"Lancet Reg. Health Eur."},{"issue":"35","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1093\/eurheartj\/eht280","article-title":"Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060","volume":"34","author":"Krijthe BP","year":"2013","unstructured":"Krijthe BP, Kunst A, Benjamin EJ Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur. Heart J. 34(35), 2746\u20132751 (2013).","journal-title":"Eur. Heart J."},{"issue":"10","key":"e_1_3_8_5_2","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/europace\/euz141","article-title":"Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project","volume":"21","author":"Di Carlo A","year":"2019","unstructured":"Di Carlo A, Bellino L, Consoli D Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 21(10), 1468\u20131475 (2019).","journal-title":"Europace"},{"issue":"36","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)","volume":"45","author":"Van Gelder IC","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur. Heart J. 45(36), 3314\u20133414 (2024).","journal-title":"Eur. Heart J."},{"issue":"8","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf PA","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983\u2013988 (1991).","journal-title":"Stroke"},{"issue":"2","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.STR.32.2.392","article-title":"Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project)","volume":"32","author":"Lamassa M","year":"2001","unstructured":"Lamassa M, Di Carlo A, Pracucci G Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 32(2), 392\u2013398 (2001).","journal-title":"Stroke"},{"issue":"6","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/01.STR.0000166053.83476.4a","article-title":"Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study","volume":"36","author":"Marini C","year":"2005","unstructured":"Marini C, De Santis F, Sacco S Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36(6), 1115\u20131119 (2005).","journal-title":"Stroke"},{"issue":"10","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"e0291575","DOI":"10.1371\/journal.pone.0291575","article-title":"Quality of life among patients with atrial fibrillation: a theoretically-guided cross-sectional study","volume":"18","author":"Rush KL","year":"2023","unstructured":"Rush KL, Seaton CL, Burton L Quality of life among patients with atrial fibrillation: a theoretically-guided cross-sectional study. PLoS ONE 18(10), e0291575 (2023).","journal-title":"PLoS ONE"},{"issue":"2","key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1524-4733.2008.00416.x","article-title":"The costs of care in atrial fibrillation and the effect of treatment modalities in Germany","volume":"12","author":"McBride D","year":"2009","unstructured":"McBride D, Mattenklotz AM, Willich SN, Br\u00fcggenj\u00fcrgen B. The costs of care in atrial fibrillation and the effect of treatment modalities in Germany. Value Health 12(2), 293\u2013301 (2009).","journal-title":"Value Health"},{"key":"e_1_3_8_12_2","doi-asserted-by":"crossref","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"Lopez-Lopez JA","year":"2017","unstructured":"Lopez-Lopez JA, Sterne JAC, Thom HHZ Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 359, j5058 (2017).","journal-title":"BMJ"},{"issue":"12","key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139\u20131151 (2009).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_8_14_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365(10), 883\u2013891 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365(11), 981\u2013992 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093\u20132104 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"9921","key":"e_1_3_8_17_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921), 955\u2013962 (2014).","journal-title":"Lancet"},{"issue":"2","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11239-020-02367-2","article-title":"Switching between direct oral anticoagulants: a systematic review and meta-analysis","volume":"52","author":"Romoli M","year":"2021","unstructured":"Romoli M, Marchetti G, Bernardini F, Urbinati S. Switching between direct oral anticoagulants: a systematic review and meta-analysis. J. Thromb. Thrombolysis 52(2), 560\u2013566 (2021).","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11239-017-1565-2","article-title":"High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy","volume":"44","author":"Manzoor BS","year":"2017","unstructured":"Manzoor BS, Walton SM, Sharp LK, Galanter WL, Lee TA, Nutescu EA. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. J. Thromb. Thrombolysis 44(4), 435\u2013441 (2017).","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"e_1_3_8_20_2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13041073","article-title":"Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation","volume":"13","author":"Deitelzweig S","year":"2024","unstructured":"Deitelzweig S, Kang A, Jiang J Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation. J. Clin. Med. 13(4), (2024).","journal-title":"J. Clin. Med."},{"issue":"1","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jval.2021.06.014","article-title":"Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications","volume":"25","author":"Neumann PJ","year":"2022","unstructured":"Neumann PJ, Podolsky MI, Basu A, Ollendorf DA, Cohen JT. Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications. Value Health 25(1), 59\u201368 (2022).","journal-title":"Value Health"},{"key":"e_1_3_8_22_2","article-title":"Getting the math right when measuring the value of new medicines","author":"Lakdawalla D","year":"2023","unstructured":"Lakdawalla D, Phelps CE, Arndorfer S, Incerti D, Masia N. Getting the math right when measuring the value of new medicines. White Paper (2023). (Accessed: 18 June 2024). https:\/\/www.nopatientleftbehind.org\/resource-materials\/4wrddq4u40fbg0gvodo7lpynk207a4","journal-title":"White Paper"},{"issue":"1","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/13696998.2025.2450933","article-title":"Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany","volume":"28","author":"Subash R","year":"2025","unstructured":"Subash R, Duan C, Shah A Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States and Germany. J. Med. Econ. 28(1), 224\u2013234 (2025).","journal-title":"J. Med. Econ."},{"issue":"1","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau D","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Value Health 25(1), 3\u20139 (2022).","journal-title":"Value Health"},{"issue":"9","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21090","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"21","author":"Sterne JA","year":"2017","unstructured":"Sterne JA, Bodalia PN, Bryden PA Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol. Assess. 21(9), 1\u2013386 (2017).","journal-title":"Health Technol. Assess."},{"issue":"7","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/heartjnl-2011-300646","article-title":"Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation","volume":"98","author":"Kansal AR","year":"2012","unstructured":"Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 98(7), 573\u2013578 (2012).","journal-title":"Heart"},{"key":"e_1_3_8_27_2","unstructured":"The independent Institute for Quality and Efficiency in Health Care (Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen I. General Methods Version 7.0. (2023). (Accessed: 14 June 2024). https:\/\/www.iqwig.de\/en\/about-us\/methods\/methods-paper\/"},{"key":"e_1_3_8_28_2","unstructured":"Statista. Gross Domestic Product per capita in the European Union in 2023 by member state. (2024). (Accessed: 18 September 2024). https:\/\/www.statista.com\/statistics\/1373462\/gdp-per-capita-eu-member-states-2022\/"},{"key":"e_1_3_8_29_2","unstructured":"World Health Organization. Macroeconomics and health: investing in health for economic development \/ report of the Commission on Macroeconomics and Health 2001. (Accessed: 18 September 2024). https:\/\/iris.who.int\/handle\/10665\/42435"},{"key":"e_1_3_8_30_2","unstructured":"GENESIS-Online Statistisches Bundesamt. 12621-0001: life table (period life table): germany years gender completed age. (2022). (Accessed: 7 August 2024). https:\/\/www-genesis.destatis.de\/genesis\/online?operation=table&code=12621-0001&bypass=true&levelindex=0&levelid=1715253114804#abreadcrumb"},{"issue":"3","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11136-010-9591-y","article-title":"Factors determining utility measured with the EQ-5D in patients with atrial fibrillation","volume":"19","author":"Berg J","year":"2010","unstructured":"Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. Qual. Life Res. 19(3), 381\u2013390 (2010).","journal-title":"Qual. Life Res."},{"issue":"1","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.STR.0000196990.69412.fb","article-title":"Long-term outcome after stroke: evaluating health-related quality of life using utility measurements","volume":"37","author":"Haacke C","year":"2006","unstructured":"Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke 37(1), 193\u2013198 (2006).","journal-title":"Stroke"},{"key":"e_1_3_8_33_2","article-title":"The University of York Centre for Health Economics","author":"Kind P","year":"1999","unstructured":"Kind P, Hardman G, Macran S. The University of York Centre for Health Economics. UK Population Norms for EQ-5D (1999). (Accessed: 10 October 2024). https:\/\/www.york.ac.uk\/che\/pdf\/DP172.pdf","journal-title":"UK Population Norms for EQ-5D"},{"issue":"1","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13561-020-00274-z","article-title":"A cost-effectiveness analysis model of preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany","volume":"10","author":"Birkemeyer R","year":"2020","unstructured":"Birkemeyer R, M\u00fcller A, Wahler S, von der Schulenburg JM. A cost-effectiveness analysis model of preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. Health Econ. Rev. 10(1), 16 (2020).","journal-title":"Health Econ. Rev."},{"issue":"1","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13561-015-0063-5","article-title":"Costs of treating cardiovascular events in Germany: a systematic literature review","volume":"5","author":"Schmid T","year":"2015","unstructured":"Schmid T. Costs of treating cardiovascular events in Germany: a systematic literature review. Health Econ. Rev. 5(1), 27 (2015).","journal-title":"Health Econ. Rev."},{"key":"e_1_3_8_36_2","unstructured":"InEK GmbH \u2013 Institute for the Remuneration System in Hospitals. Catalogue of flat rates per case 2024. (2024). (Accessed: 30 July 2024). https:\/\/www.g-drg.de\/ag-drg-system-2024\/fallpauschalen-katalog\/fallpauschalen-katalog-20242"},{"key":"e_1_3_8_37_2","unstructured":"CGM LAUER. LAUER-TAXE online 4.0. (2024). (Accessed: 4 July 2024). https:\/\/portal.cgmlauer.cgm.com\/LF\/default.aspx?p = 12000%09%20"},{"key":"e_1_3_8_38_2","unstructured":"Destatis Statistisches Bundesamt. Consumer price index and inflation rate. (Accessed: 1 May 2024). https:\/\/www.destatis.de\/DE\/Themen\/Wirtschaft\/Preise\/Verbraucherpreisindex\/_inhalt.html"},{"key":"e_1_3_8_39_2","unstructured":"Bayer. European Patent Office maintained Bayer patent on the once-daily administration of rivaroxaban (Xarelto\u2122). (2021). (Accessed: 14 March 2025). https:\/\/www.bayer.com\/media\/en-us\/european-patent-office-maintained-bayer-patent-on-the-once-daily-administration-of-rivaroxaban-xareltotm\/"},{"key":"e_1_3_8_40_2","unstructured":"Bristol Myers Squibb. Investor statement on Eliquis revenue under IRA. (2024). (Accessed: 14 March 2025). https:\/\/www.bms.com\/investor-statement-on-eliquis-revenue-under-ira.html"},{"key":"e_1_3_8_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15021"},{"key":"e_1_3_8_42_2","volume-title":"ISPOR\u2014The Professional Society for Health Economics and Outcomes Research","author":"Subash R","year":"2024","unstructured":"Subash R, Shah A, Duan C, Hines D, Zhang M, Hagan M. Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in Germany. Presented at: ISPOR\u2014The Professional Society for Health Economics and Outcomes Research, GA, USA (5\u20138 May 2024). Poster EE288."},{"key":"e_1_3_8_43_2","volume-title":"ISPOR\u2014The Professional Society for Health Economics and Outcomes Research","author":"Subash R","year":"2024","unstructured":"Subash R, Shah A, Duan C, Hines D, Zhang M, Hagan M. Decision model to evaluate the cost of clinical events associated with switching from apixaban to rivaroxaban among patients with non-valvular atrial fibrillation in the United States. Presented at: ISPOR\u2014The Professional Society for Health Economics and Outcomes Research, GA, USA (5\u20138 May 2024). Poster EE188."},{"issue":"2","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14737167.2020.1798233","article-title":"Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients","volume":"21","author":"Walter E","year":"2021","unstructured":"Walter E, Voit M, Eichhober G. Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients. Expert Rev. Pharmacoecon. Outcomes Res. 21(2), 265\u2013275 (2021).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"2","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","article-title":"Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"36","author":"Lip GY","year":"2014","unstructured":"Lip GY, Kongnakorn T, Phatak H Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin. Ther. 36(2), 192\u2013210.e20 (2014).","journal-title":"Clin. Ther."},{"key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/CEOR.S317078","article-title":"Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among finnish patients with non-valvular atrial fibrillation","volume":"13","author":"Hallinen T","year":"2021","unstructured":"Hallinen T, Soini E, Asseburg C Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among finnish patients with non-valvular atrial fibrillation. Clinicoecon. Outcomes Res. 13, 745\u2013755 (2021).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"8","key":"e_1_3_8_47_2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/heartjnl-2016-309901","article-title":"Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation","volume":"103","author":"Bahit MC","year":"2017","unstructured":"Bahit MC, Lopes RD, Wojdyla DM Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 103(8), 623 (2017).","journal-title":"Heart"},{"issue":"6","key":"e_1_3_8_48_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf J","year":"2014","unstructured":"Beyer-Westendorf J, F\u00f6rster K, Pannach S Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124(6), 955\u2013962 (2014).","journal-title":"Blood"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T13:39:57Z","timestamp":1749562797000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":46,"alternative-id":["10.57264\/cer-2025-0008"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0008","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"article-number":"e250008"}}